Gabather AB (publ) (GABA.ST)
SEK 0.4
(-3.61%)
SEK 0.4
(-3.61%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.87 Million SEK | 107.54% |
| 2022 | 3.31 Million SEK | -25.16% |
| 2021 | 4.42 Million SEK | 33.74% |
| 2020 | 3.31 Million SEK | 33.7% |
| 2019 | 2.47 Million SEK | 7.99% |
| 2018 | 2.29 Million SEK | -5.22% |
| 2017 | 2.41 Million SEK | 55.05% |
| 2016 | 1.56 Million SEK | 114.55% |
| 2015 | 727.31 Thousand SEK | 38.47% |
| 2014 | 525.26 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 6.84 Million SEK | -0.52% |
| 2024 Q2 | 6.42 Million SEK | -6.05% |
| 2023 FY | 6.87 Million SEK | 107.54% |
| 2023 Q3 | 5.09 Million SEK | -3.23% |
| 2023 Q1 | 5.91 Million SEK | 78.46% |
| 2023 Q2 | 5.26 Million SEK | -11.01% |
| 2023 Q4 | 6.87 Million SEK | 35.05% |
| 2022 Q1 | 2.14 Million SEK | -51.47% |
| 2022 Q3 | 2.61 Million SEK | 4.43% |
| 2022 FY | 3.31 Million SEK | -25.16% |
| 2022 Q4 | 3.31 Million SEK | 26.54% |
| 2022 Q2 | 2.5 Million SEK | 16.71% |
| 2021 FY | 4.42 Million SEK | 33.74% |
| 2021 Q2 | 2.86 Million SEK | -26.9% |
| 2021 Q4 | 4.42 Million SEK | 69.46% |
| 2021 Q3 | 2.61 Million SEK | -8.7% |
| 2021 Q1 | 3.91 Million SEK | 18.24% |
| 2020 Q3 | 2.38 Million SEK | 3.56% |
| 2020 FY | 3.31 Million SEK | 33.7% |
| 2020 Q1 | 3.04 Million SEK | 23.08% |
| 2020 Q4 | 3.31 Million SEK | 38.88% |
| 2020 Q2 | 2.3 Million SEK | -24.48% |
| 2019 Q2 | 3.05 Million SEK | 88.98% |
| 2019 Q1 | 1.61 Million SEK | -29.58% |
| 2019 Q4 | 2.47 Million SEK | 28.98% |
| 2019 FY | 2.47 Million SEK | 7.99% |
| 2019 Q3 | 1.92 Million SEK | -37.09% |
| 2018 FY | 2.29 Million SEK | -5.22% |
| 2018 Q2 | 2.43 Million SEK | 17.15% |
| 2018 Q4 | 2.29 Million SEK | -15.69% |
| 2018 Q3 | 2.72 Million SEK | 11.84% |
| 2018 Q1 | 2.07 Million SEK | -14.2% |
| 2017 FY | 2.41 Million SEK | 55.05% |
| 2017 Q1 | 1.93 Million SEK | 24.0% |
| 2017 Q4 | 2.41 Million SEK | 65.04% |
| 2017 Q3 | 1.46 Million SEK | -7.8% |
| 2017 Q2 | 1.59 Million SEK | -17.83% |
| 2016 Q4 | 1.56 Million SEK | 33.72% |
| 2016 Q2 | 1.98 Million SEK | 55.93% |
| 2016 Q1 | 1.27 Million SEK | 75.03% |
| 2016 FY | 1.56 Million SEK | 114.55% |
| 2016 Q3 | 1.16 Million SEK | -41.21% |
| 2015 Q3 | 562 Thousand SEK | -60.28% |
| 2015 FY | 727.31 Thousand SEK | 38.47% |
| 2015 Q2 | 1.41 Million SEK | 152.23% |
| 2015 Q1 | 561 Thousand SEK | 6.86% |
| 2015 Q4 | 727.31 Thousand SEK | 29.41% |
| 2014 Q4 | 525 Thousand SEK | 0.0% |
| 2014 FY | 525.26 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AcuCort AB | 10.97 Million SEK | 37.33% |
| AlzeCure Pharma AB (publ) | 8.22 Million SEK | 16.397% |
| BioGaia AB (publ) | 302.84 Million SEK | 97.729% |
| Enzymatica AB (publ) | 49.3 Million SEK | 86.049% |
| Enorama Pharma AB (publ) | 14.84 Million SEK | 53.674% |
| Klaria Pharma Holding AB (publ.) | 31.98 Million SEK | 78.497% |
| Moberg Pharma AB (publ) | 24 Million SEK | 71.35% |
| Nanexa AB (publ) | 36.42 Million SEK | 81.118% |
| Newbury Pharmaceuticals AB (publ) | 38.95 Million SEK | 82.343% |
| ODI Pharma AB | 10.05 Million SEK | 31.614% |
| Orexo AB (publ) | 727.7 Million SEK | 99.055% |
| Probi AB (publ) | 181.31 Million SEK | 96.207% |
| Swedencare AB (publ) | 2.31 Billion SEK | 99.703% |
| Swedish Orphan Biovitrum AB (publ) | 40.16 Billion SEK | 99.983% |
| Toleranzia AB | 6.9 Million SEK | 0.449% |
| Vivesto AB | 30.45 Million SEK | 77.414% |